Divisions of Gastroenterology and Pediatrics, "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo (FG), Italy.
Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2744-2747. doi: 10.26355/eurrev_202103_25437.
From September 2020, a second wave of COVID-19 pandemic started. We aimed at exploring the impact of SARS-CoV-2 infection in IBD patients during the two waves.
All IBD patients with a confirmed diagnosis of SARS-CoV-2 infection were enrolled. They were sorted into two groups (those infected before September 2020, and those from September 2020 to January 2021) and compared by demographic and clinical data.
Twenty-five patients (out of about 600 with a follow-up visit) were infected with SARS-CoV-2 (4.1%). Sixteen were male and the mean age was 46.5 ± 14.3 years (range 24-74). Six were smokers and 11 had comorbidities; 2 were on steroids and 17 on immunosuppressants or biologics. Three patients (12%) needed hospitalization and other three patients were treated with azithromycin, steroids and LMWH, all of them during the second wave. No patient died or developed any sequelae. Two subjects were infected during the first wave (0.3 vs. 3.83, p<0.0001). Non-significant differences were found between the two groups.
A higher number of IBD patients were infected during the second wave. No patient developed a severe form of pneumonia, even those treated with immunosuppressants or biologics. No risk factor for hospitalization was found.
自 2020 年 9 月起，第二波 COVID-19 疫情开始。我们旨在探讨 COVID-19 感染对 IBD 患者在两波疫情期间的影响。
所有确诊 SARS-CoV-2 感染的 IBD 患者均被纳入研究。将他们分为两组（2020 年 9 月前感染的患者和 2020 年 9 月至 2021 年 1 月感染的患者），并比较两组的人口统计学和临床数据。
共有 25 名患者（约 600 名随访患者中的 4.1%）感染了 SARS-CoV-2。16 名男性，平均年龄为 46.5 ± 14.3 岁（范围 24-74）。6 名吸烟者，11 名合并症患者；2 名正在使用类固醇，17 名正在使用免疫抑制剂或生物制剂。3 名患者（12%）需要住院治疗，另外 3 名患者在第二波疫情期间接受了阿奇霉素、类固醇和低分子肝素治疗。没有患者死亡或出现任何后遗症。2 名患者在第一波疫情期间感染（0.3%比 3.83%，p<0.0001）。两组之间未发现显著差异。
在第二波疫情期间，更多的 IBD 患者感染。即使接受免疫抑制剂或生物制剂治疗的患者也未发生严重肺炎。未发现住院的危险因素。
